Valion Bio Inc
NASDAQ: VBIO · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-09-11
Valion Bio Inc (VBIO) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2013 | 2013 | 2014 | 2014 | 2015 | 2015 | 2016 | 2016 | 2017 | 2017 | 2018 | 2019 | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $245680.00 | $245680.00 | $248350.00 | $248348.00 | $163360.00 | $163363.00 | $102420.00 | $102419.00 | $258288.00 | — | $0.00 | — | $0.00 | $1.84M | $1.18M | $0.00 | $382000.00 |
| Revenue growth (YoY) | — | — | — | — | +0.0% | +1.1% | -0.0% | -34.2% | +0.0% | -37.3% | -0.0% | +152.2% | -100.0% | — | — | — | — | -36.1% | -100.0% | — |
| Cost of revenue | — | — | $156400.00 | $121340.00 | $121341.00 | $149480.00 | $149478.00 | $108260.00 | $108255.00 | $77940.00 | $77943.00 | $454767.00 | — | — | — | — | $1.54M | $889000.00 | $352000.00 | $350000.00 |
| Gross profit | — | — | $-156400.00 | $124340.00 | $124339.00 | $98870.00 | $98870.00 | $55100.00 | $55108.00 | $24480.00 | $24476.00 | $-196479.00 | — | — | — | — | $299000.00 | $287000.00 | $-352000.00 | $32000.00 |
| Gross margin | — | — | — | 50.6% | 50.6% | 39.8% | 39.8% | 33.7% | 33.7% | 23.9% | 23.9% | -76.1% | — | — | — | — | 16.3% | 24.4% | — | 8.4% |
| R&D | $255000.00 | $580000.00 | $575092.00 | $1.13M | $1.13M | $613120.00 | $613119.00 | $893960.00 | $893960.00 | $1.90M | $1.90M | $1.80M | $1.01M | $1.01M | $408905.00 | $408905.00 | $1.73M | $1.66M | $1.31M | $3.13M |
| SG&A | $2.55M | $3.02M | $2.87M | $2.80M | $2.80M | $2.23M | $2.23M | $2.63M | $2.63M | $2.52M | $2.52M | $4.14M | $2.68M | $2.68M | $1.93M | $1.93M | $5.88M | $4.75M | $3.16M | $4.77M |
| Operating income | — | $-3.60M | $-3.60M | $-3.81M | $-3.81M | $-2.74M | $-2.74M | $-3.47M | $-3.47M | $-4.40M | $-4.40M | $-5.68M | $-3.69M | $-3.69M | $-2.34M | $-2.34M | $-10.10M | $-8.24M | $-4.42M | $-7.90M |
| Operating margin | — | — | — | -1548.8% | -1548.8% | -1104.0% | -1104.0% | -2125.1% | -2125.1% | -4292.9% | -4292.9% | -2199.9% | — | — | — | — | -548.8% | -701.1% | — | -2067.5% |
| EBITDA | — | $-3.75M | — | $-4.04M | — | $-140967.00 | — | $-5.22M | — | $-4.31M | $-4.31M | $-13.10M | $-3.69M | — | $-880851.00 | — | $-9.92M | $-8.06M | $-4.06M | $-7.84M |
| EBITDA margin | — | — | — | -1645.4% | 0.0% | -56.8% | 0.0% | -3194.4% | 0.0% | -4207.2% | -4207.2% | -5072.8% | — | — | — | — | -539.3% | -685.6% | — | -2052.9% |
| EBIT | — | $-3.60M | $-3.40M | $-3.81M | $-4.04M | $-2.74M | $-140962.00 | $-3.47M | $-5.22M | $-4.40M | $-4.40M | $-4.57M | $-4.44M | $-3.69M | $-2.34M | $-2.34M | $-10.10M | $-8.24M | $-4.42M | $-7.85M |
| Interest expense | $0.00 | $404317.00 | $0.00 | $6065.00 | $0.00 | $363.00 | $0.00 | $1010.00 | $0.00 | — | $0.00 | $0.00 | $6782.00 | $0.00 | — | $0.00 | — | — | $0.00 | $146000.00 |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | — | $-4.15M | $-4.15M | $-4.05M | $-4.05M | $-141330.00 | $-141325.00 | $-5.22M | $-5.22M | $-4.31M | $-4.31M | $-13.12M | $-4.37M | $-4.37M | $-880851.00 | $-880851.00 | $-10.10M | $-8.24M | $-5.66M | $-8.88M |
| Net income growth (YoY) | — | — | -0.1% | +2.5% | -0.0% | +96.5% | +0.0% | -3593.2% | +0.0% | +17.4% | +0.0% | -204.5% | +66.7% | +0.0% | +79.8% | +0.0% | -1046.2% | +18.3% | +31.4% | -57.0% |
| Profit margin | — | — | — | -1647.8% | -1647.8% | -56.9% | -56.9% | -3195.0% | -3195.0% | -4207.2% | -4207.2% | -5080.2% | — | — | — | — | -548.7% | -701.0% | — | -2324.1% |
Frequently asked questions
What is Valion Bio Inc's revenue?
Valion Bio Inc's trailing twelve-month revenue is $-86000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is VBIO?
In its most recent fiscal year, VBIO ran a gross margin of 8.38%, an operating margin of -2,067.54%, and a net margin of -2,324.08%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does VBIO generate?
VBIO produced $-7.04M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is VBIO's balance sheet healthy?
VBIO holds $12.64M in cash and equivalents against $6.45M in long-term debt, on $16.80M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.